Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity TranscriptSeeking Alpha • 03/30/26
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate HighlightsGlobeNewsWire • 03/24/26
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026GlobeNewsWire • 03/14/26
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 MilestonesGlobeNewsWire • 01/12/26
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/17/25
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025GlobeNewsWire • 12/09/25
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)GlobeNewsWire • 12/05/25
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)GlobeNewsWire • 12/01/25
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 12/01/25
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025GlobeNewsWire • 11/05/25
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate HighlightsGlobeNewsWire • 11/04/25
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor AgonistGlobeNewsWire • 10/27/25
Biomea Fusion, Inc. (BMEA) Presents at Citi's 2025 SMID Cap Biopharma Call Series TranscriptSeeking Alpha • 10/23/25
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat SeriesGlobeNewsWire • 10/21/25
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient PopulationsGlobeNewsWire • 10/06/25
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/01/25
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate UpdateGlobeNewsWire • 09/16/25
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate HighlightsGlobeNewsWire • 08/05/25